Noteworthy

Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
Feb 01, 2011
Pharmaceutical Executive
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
Jan 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest
Jan 01, 2011
Pharmaceutical Executive
It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
Jan 01, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Jan 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Amgen's hub-and-spoke system combines control at home with the flexibility to respond to local needs
Jan 01, 2011
Pharmaceutical Executive
Building the commercial and policy base for effective collaboration in biotech
Jan 01, 2011
Pharmaceutical Executive
A surve of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade
Jan 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
US Pharmacopeia has launched an ambitious moderniation campaign to ensure its standards keep pace with changes in the blobal marketplace
native1_300x100
lorem ipsum